Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction

Journal of the American College of Cardiology

Volumn 39, Issue 1, 2002, Pages 142-147

  Clozel, Martine ^a   Qiu, Changbin ^a,b   Qiu, Chang Shen ^a,b   Hess, Patrick ^a   Clozel, Jean Paul ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; RO 61 0612 10; TEZOSENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; LUNG EDEMA; LUNG WEIGHT; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; DISEASE MODELS, ANIMAL; HEMODYNAMIC PROCESSES; LUNG; MALE; MYOCARDIAL INFARCTION; ORGAN SIZE; PULMONARY EDEMA; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, ENDOTHELIN; TETRAZOLES; VASODILATOR AGENTS;

EID: 0037005775     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01692-8     Document Type: Article

References (42)

1. Endothelin in chronic heart failure: Current position and future prospects
2. Endothelin antagonism with bosentan: A review of potential applications
3. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure
4. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: Beneficial effects on left ventricular and myocyte function
5. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure: Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan)
6. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure
7. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
8. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction
9. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
10. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
11. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
12. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
13. Plasma endothelin-1 levels in stable and unstable angina
14. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: Possible involvement of myocardial endothelin system in ventricular remodeling
15. ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats
16. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use
17. Effects of endothelins on collagen turnover in cardiac fibroblasts
18. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats: Comparison with angiotensin-converting enzyme inhibition and calcium antagonism
19. Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats
20. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo: Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist
21. Cardiac and vascular hypertrophy in hypertension due to angiotensin II: Effect of losartan and bosentan
22. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: Marked increase in endothelin-1 production in the failing heart
23. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats
24. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome
25. Effects of endothelin-1 on vascular permeability in the conscious rat: Interactions with platelet-activating factor
26. Protective effects of BQ-123, an ETA receptor antagonist, against leukotoxin-induced injury in rat lungs
27. Endothelin-1 potentiates leukotoxin-induced edematous lung injury
28. A role for endothelin in bicuculline-induced neurogenic pulmonary oedema in rats
29. Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat
30. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade
31. Role for endogenous endothelin in the regulation of plasma volume and albumin escape during endotoxin shock in conscious rats
32. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels
33. Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat
34. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig
35. The nonpeptide endothelin receptor antagonist bosentan enhances myocardial recovery and endothelial function during reperfusion of the ischemic rat heart
36. Role of endothelin during reperfusion after ischemia in isolated perfused rat heart
37. Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: Studies with bosentan, a mixed ETA-ETB antagonist
38. Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction
39. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat
40. LU135252, an endothelin(A) receptor antagonist, did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction
41. Endothelin antagonism in experimental ischemic heart failure: Hemodynamic, structural and neurohumoral effects
42. Hemodynamic effect of endothelin antagonists in dogs with myocardial infarction